IDENIX REPORTS INTERIM ANALYSIS OF A PHASE IIA TRIAL OF VALOPICITABINE IN COMBINATION WITH PEGYLATED INTERFERON

Idenix Pharmaceuticals has announced interim clinical trial data for valopicitabine (NM283), the company's lead drug candidate for the treatment of hepatitis C.

In this Phase IIa trial, patients are randomized to one of two treatment arms, valopicitabine (NM283) monotherapy, or valopicitabine (NM283) plus pegylated interferon. This interim data analysis includes all 19 patients who have completed 12 weeks of treatment in this trial. The patients receiving the combination of NM283 and pegylated interferon achieved a mean reduction of serum HCV RNA of 99.94 percent, at Week 12.